Gilead Sciences, based in Foster City, California, announced it will launch two Phase III clinical trials of its investigational antiviral drug remdesivir in adults diagnosed with COVID-19, the disease caused by the novel coronavirus. The outbreak began in China in…
Allecra’s Exblifep Effective in Hospital-Based Urinary Tract Infections
Allecra Therapeutics, with locations in Saint-Louis, France and Weil, Am Rhein, Germany, indicated its Exblifep (cefepime-enmetazobactam) hit pre-specified primary endpoints in its Phase III ALLIUM clinical trial in complicated urinary tract infections (cUTI), including acute pyelonephritis (AP). It also demonstrated…
Chinese biotech censured for misleading coronavirus drug claims
China’s BrightGene Bio-Medical Technology has been censured by the Shanghai Stock Exchange for wrongly claiming it is able to manufacture Gilead’s experimental drug remdesivir – scientists’ best hope of a treatment for the novel coronavirus. Shares in BrightGene tanked after…
Boehringer bags CHMP backing for Ofev in rare lung disease
Boehringer Ingelheim has moved a step closer to getting approval for its blockbuster respiratory drug Ofev as the first treatment in the EU for a rare, life-threatening fibrotic disease. The EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended…
Gilead to buy immuno-oncology firm Forty Seven for $4.9bn
Gilead is to buy immuno-oncology firm Forty Seven for $4.9 billion, adding an antibody targeting several blood cancers to its research pipeline. Forty Seven is based in Menlo Park, a short drive away from Gilead’s base in Foster City, and…
